AxoGen, Inc. Makes First Commercial Shipment of Avance® Nerve Graft to Distributor in Italy
Published: Jul 16, 2012
ALACHUA, Fla.--(BUSINESS WIRE)--AxoGen, Inc. (OTCBB:AXGN), a leading regenerative medicine company focused on the development and commercialization of products and technologies for peripheral nerve reconstruction and regeneration, today announced approval by the Rizzoli Orthopaedic Institute of its first commercial shipment of Avance® Nerve Graft to MD for Life, its new distribution partner in Italy. Avance® Nerve Graft is a processed nerve allograft for bridging nerve discontinuities (gaps created when nerves are severed). By eliminating a second surgery to harvest the patient’s own nerve tissue for use in the repair, Avance® Nerve Graft offers an alternative to traditional autograft nerve repair procedures.